Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain metastases.[1]
^Richards G, Mehta M (2007). "Motexafin gadolinium in the treatment of brain metastases". Expert Opinion on Pharmacotherapy. 8 (3): 351–9. doi:10.1517/14656566.8.3.351. PMID 17266469. S2CID 25542776.
and 9 Related for: Motexafin gadolinium information
Motexafingadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible...
cancer, infections, and other diseases. The drugs hydroxyurea and Motexafingadolinium interfere with the action of this enzyme. Elledge SJ, Zhou Z, Allen...
the form of Motexafingadolinium and Motexafin lutetium which are used as chemotherapeutics in the treatment of cancer. The two Motexafin compounds showed...
cellular ROS stress level, either by direct ROS-generation (e.g. motexafingadolinium, elesclomol) or by agents that abrogate the inherent antioxidant...
radiosensitisers (Xcytrin) and chemosensitisers. Xcytrin, a gadolinium texaphyrin (motexafingadolinium), has been evaluated in Phase III clinical trials against...
Ford JM, Daniels MJ, Erhardt RJ, Frazer BH, et al. (January 2006). "Motexafin-gadolinium taken up in vitro by at least 90% of glioblastoma cell nuclei". Clinical...
types of cancer, including malignant mesothelioma. For example, motexafingadolinium (MGd) is a new chemotherapeutic agent that selectively targets tumor...